Navigation Links
Cornerstone Therapeutics Announces Collaboration with The Cough Company
Date:8/2/2010

CARY, N.C., Aug. 2 /PRNewswire-FirstCall/ -- Cornerstone Therapeutics Inc. (Nasdaq: CRTX) ("Cornerstone" or the "Company"), a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets, today announced that the Company has entered into a License Agreement and a Development Agreement with Alitair Pharmaceuticals, Inc, also known as The Cough Company ("The Cough Company").  Under the terms of the agreement, Cornerstone has acquired a license to certain of The Cough Company's proprietary intellectual property and the companies will collaborate in developing one or more products to treat respiratory diseases.  

The Cough Company has a portfolio of patents pending, which relate to its proprietary drug delivery system.  This portfolio includes claims covering solid oral dosage formulations in a wide variety of therapeutic categories.  Cornerstone intends to leverage this intellectual property to develop one or more proprietary, patent-protected cough and cold products.  

"We view The Cough Company as an important partner in the continued development of our cough and cold franchise, which is a key aspect of our growth strategy," said Craig A. Collard, Cornerstone's President and Chief Executive Officer.  "This collaboration has the potential to significantly enhance our pipeline, which already includes multiple innovative product candidates in the respiratory space."

"Cornerstone provides the respiratory marketing expertise which we believe will translate our development program into multiple commercial successes," said William Howard, Ph.D., President of The Cough Company.  "We look forward to moving our platform forward with Cornerstone's support."

Pursuant to the agreement, Cornerstone will make an upfront one-time payment and has committed to making subsequent success-based milestone payments, as well as royalties based on any future net sales of licensed products.  Cornerstone's rights to The Cough Company's intellectual property are exclusive as long as the parties are actively collaborating on any product development.  

About Cornerstone Therapeutics

Cornerstone Therapeutics Inc. (Nasdaq: CRTX), headquartered in Cary, N.C., is a specialty pharmaceutical company focused on acquiring, developing and commercializing significant products primarily for the respiratory and related markets.  The Company currently promotes multiple marketed products in the United States to respiratory-focused physicians, key retail pharmacies and hospitals with its specialty sales forces.  The Company also has a late-stage clinical pipeline with a recent regulatory submission filing and four additional regulatory approval submissions targeted within the next three years.  Key elements of the Company's strategy are to in-license or acquire rights to under-promoted, patent-protected, branded respiratory or related pharmaceutical products, or late-stage product candidates; implement life cycle management strategies to maximize the potential value and competitive position of the Company's currently marketed products, newly acquired products and product candidates that are currently in development; grow product revenue through the Company's specialty sales forces; and maintain and strengthen the intellectual property position of the Company's currently marketed products, newly acquired products and product candidates.

About The Cough Company

The Cough Company is a division of Alitair Pharmaceuticals, Inc, a privately held drug development company with products under development in the respiratory, pain and women's health categories.

Safe Harbor Statement

This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained herein, other than statements of historical fact, including statements regarding the progress and timing of our licensing transactions, our product development programs and related trials, our strategy and our future operations and opportunities, constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including our development programs, the results of preclinical studies and clinical trials with respect to our products under development, our ability to enter into collaboration or other license arrangements with respect to our technology on commercially reasonable terms or at all, our ability to obtain and maintain protection for the intellectual property we own or license from third parties, our ability to satisfy FDA and other regulatory requirements and the other factors described in Item 1A (Risk Factors) of our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the SEC) on March 4, 2010 and in our subsequent filings with the SEC. In addition, the statements in this press release reflect our expectations and beliefs as of the date of this release, should not be relied upon as representing our views as of any other date and do not reflect the potential impact of any acquisitions, mergers, dispositions, business development transactions, joint ventures or investments that we may make or enter into. We anticipate that subsequent events and developments will cause our expectations and beliefs to change. However, while we may elect to update these forward-looking statements publicly at some point in the future, we specifically disclaim any obligation to do so, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE Cornerstone Therapeutics Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Cornerstone Therapeutics to Host Second Quarter 2010 Conference Call
2. Cornerstone Therapeutics Announces Management Change
3. Cornerstone Therapeutics To Present at Deutsche Banks 35th Annual Healthcare Conference
4. Cornerstone Therapeutics to Host First Quarter 2010 Conference Call
5. Cornerstone Therapeutics to Present at the 30th Annual Cowen & Company Health Care Conference
6. Cornerstone Therapeutics to Host Conference Call to Discuss Financial Guidance for 2010
7. Cornerstone Therapeutics Provides a Response to FDA Warning Letter on Deconsal
8. Cornerstone Pharmaceuticals Adds Acclaimed Cancer Research Pioneer Robert A. Weinberg, Ph.D. to Its Scientific Advisory Board
9. Hepatitis C Therapeutics Market - Taiwan
10. Orexigen® Therapeutics Announces Publication of COR-I Phase 3 Study of Contrave in Lancet
11. Orexigen® Therapeutics Schedules August 5, 2010 Webcast Discussion of Financial Results for the Second Quarter Ended June 30, 2010
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... 2017  Jazz Pharmaceuticals plc (Nasdaq: JAZZ ) ... in a Phase 3 clinical trial comparing the efficacy ... in the prevention of hepatic veno-occlusive disease (VOD) in ... (HSCT) who are at high risk or at very ... will be conducted across approximately 100 medical centers in ...
(Date:1/17/2017)... According to a new market research report "Neural Network Software Market by Type (Data ... - Global Forecast to 2021" published by MarketsandMarkets, the market to expand from ... Compound Annual Growth Rate (CAGR) of 33.2%. Continue ... ... ...
(Date:1/17/2017)...  OrthoAccel ® Technologies, Inc. announces that the ... "The Effect of Vibration on Molar Distalization," a study ... S. Jay Bowman , this prospective, peer-reviewed clinical study ... Technology ® speeds up molar distalization rates in ... of days to move the upper molars into a ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... January 17, 2017 , ... ... the Montclair State University’s Athletic Training Education program forged a relationship built upon ... Education Program, which is consists of both student members and certified members ...
(Date:1/16/2017)... , ... January 17, 2017 , ... Recently, patients and ... Southwest Michigan, joined other volunteers and organizations in support of the annual Binder Park ... and families dressed up in colorful costumes of all designs coming out to enjoy ...
(Date:1/16/2017)... ... 2017 , ... Gym Source, America’s leading retailer of premium residential and commercial ... Jersey. , “We are elated to be opening this new showroom,” explains Tom Richard, ... give clients a seamless and motivating shopping experience.” , Every fitness journey is unique, ...
(Date:1/16/2017)... ... January 16, 2017 , ... With the Grand Opening Event planned for February ... by sports teams and the general public. Built in five months by Centerpoint, the ... converted into basketball or pickleball courts. The space is also suitable for indoor soccer ...
(Date:1/16/2017)... ... 16, 2017 , ... Houston dentist, Dr. Behzad Nazari, announces ... consultations and financing for orthodontics for a limited time. Complimentary for a limited ... their orthodontic options. Walk-in, late-evening, Saturday, and same-day appointments are available. Antoine Dental ...
Breaking Medicine News(10 mins):